Physician profile
Christopher C Glisson
NPI 1932254745
$124,923.16
in general payments reported to CMS, 2019-2025
16 companies · $910 in 2025
The $910 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $11K · 2021: $13K · 2022: $36K · 2023: $15K · 2024: $512 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,370 · Consulting Fee: $7,125 · Food and Beverage: $1,768 · Travel and Lodging: $215 · Honoraria: $200 · Education: $93.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,370.00 |
| Consulting Fee | $7,125.00 |
| Food and Beverage | $1,768.26 |
| Travel and Lodging | $215.46 |
| Honoraria | $200.00 |
| Education | $93.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $92,195.66 | 2019-2025 | Soliris, Ultomiris |
| Horizon Therapeutics Plc | $19,681.18 | 2020-2023 | Uplizna |
| Argenx US, INC. | $7,852.37 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Catalyst Pharmaceuticals, INC. | $3,700.38 | 2019 | |
| Genentech USA, INC. | $268.81 | 2020-2025 | Ocrevus |
| Eisai INC. | $223.91 | 2024-2025 | |
| Ucb, INC. | $159.60 | 2025 | Rystiggo, Nayzilam |
| Novartis Pharmaceuticals Corporation | $151.66 | 2023-2025 | |
| Eyepoint US, INC. | $125.00 | 2021 | |
| Lundbeck LLC | $124.97 | 2024 | Vyepti |
| Tg Therapeutics, INC. | $112.24 | 2024 | |
| Janssen Pharmaceuticals, INC | $99.99 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $91.25 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $72.33 | 2020-2022 | |
| Abbvie INC. | $44.35 | 2020-2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $19.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Glisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.